S
ubstance P (SP), the most extensively studied and potent member of the tachykinin family, is a modulator of neuroimmunoregulation, in particular the immune functions of mononuclear phagocytes. SP specifically activates NF-B, a transcription factor involved in the control of cytokine expression (1, 2) , and stimulates human peripheral blood monocytes to produce inflammatory cytokines including IL-1, IL-6, IL-12, and tumor necrosis factor ␣ (TNF-␣) (3) (4) (5) . These cytokines alter HIV expression in T cells and monocytes in vitro (6, 7) .
SP has an autocrine regulation role in macrophage function (8, 9) . For example, in the macrophage cell line P388D1, anti-SP antibody depletion of macrophage-secreted SP from the culture resulted in abrogation of SP-increased IL-1 production (8) . The pretreatment of rats with the SP antagonist CP-96,345 inhibited Clostridium difficile toxin A-mediated TNF-␣ release from isolated lamina propria macrophages. Furthermore, lamina propria macrophages obtained from the toxin A-injected ileal loops incubated in vitro with CP-96,345 had reduced TNF-␣ release, indicating an autocrine stimulation of SP in the cytokine secretion (9) . Autocrine regulation of SP also has been suggested in other cell types (10) (11) (12) . SP autocrine regulation in monocytederived macrophages (MDM) is further supported by the presence of specific cell membrane SP receptors (13) and production of SP protein by macrophages (8, 9, (14) (15) (16) (17) . SP mRNA and protein are present in monocyte͞macrophages and lymphocytes isolated from human peripheral blood (16, 18) . We have also identified the presence of neurokinin-1 receptor (NK-1R) mRNA in these cells (16, 18) . Because SP is secreted by human monocyte͞macrophages and participates in immunoregulation in an autocrine fashion (8, 9, 14, 16, 19) , it may have a role in the pathogenesis of immune-mediated diseases, including neuroimmunologic diseases and HIV͞AIDS.
SP and its receptor, NK-1R, may be involved in the modulation of HIV infection both in vivo and in vitro. Azzari et al. (20) , using a RIA, observed that HIV-positive children had higher plasma levels of SP compared with HIV-negative children. Annunziata et al. (21) showed that SP plays a critical role in HIV gp120-induced increases in permeability of rat brain endothelium cultures, and this effect of SP on gp120-induced increase in albumin permeability is abrogated by the SP antagonist (spantide) and͞or anti-SP polyclonal antibody. Significant SP immunoreactivity has been observed in HIV gp120 transgenic mouse brain vessels in comparison with nontransgenic mouse brain vessels, suggesting that SP is involved in HIV gp120-induced changes in the vascular component of the blood-brain barrier (12) . We previously reported that SP modulated HIV replication in human peripheral blood MDM in vitro (22) . We have demonstrated elevated plasma levels of SP in HIV-positive men in comparison with high-risk HIV-negative men (unpublished data).
We, therefore, postulated that SP and its receptors are actively involved in HIV infection of human immune cells such as MDM. We further postulated that by interrupting the SP autocrine loop, SP antagonists inhibit HIV infection of these cells. We report here that the nonpeptide SP antagonist (CP-96,345) potently inhibits HIV infection of MDM.
Materials and Methods
Cells. Peripheral blood was obtained from healthy normal adult donors. The blood samples were identified as HIV-1 antibody negative by anonymous testing with the ELISA method (Coulter). Monocytes were purified according to our previously described techniques (23, 24) .
ACH-2 and U38 cell lines (25, 26) were obtained from the National Institutes of Health AIDS reagent program. DNA extracted from ACH-2 cells was used as a positive standard for HIV DNA PCR as reported (27) . The U38 cell line contains stably integrated, silent copies of the HIV long-terminal repeat (LTR) promoter linked to the chloramphenicol acetyltransferase (CAT) gene and was used to study the effect of SP and͞or CP-96,345 on the activation of HIV LTR promoter.
Anti-CXCR4-FITC was obtained from R & D Systems. SP, a rabbit anti-SP antibody, and lipopolysaccharide (LPS) were obtained from Sigma. Sodium azide was removed from the anti-SP antibody by using CHROMA SPIN STE-30 columns (CLONTECH). The nonpeptide SP antagonist, CP-96,345, and  its 2R,3R inactive enantiomer, CP-96,344 (28), were generously  provided by Pfizer Diagnostics. CP-96,345 and CP-96,344 were  dissolved in FPLC grade H 2 O at the concentration of 10   Ϫ3 M, filtered through a 0.22-m filter (Millipore), and stored at Ϫ70°C.
HIV Strains.
Based on their differential use of the major HIV coreceptors, HIV isolates have been referred to as R5, X4, or R5X4 strains (29) . The M-tropic R5 prototype strains (Bal and ADA), dual tropic strain (89.6), and X4 primary isolate (UG024) were obtained from the National Institutes of Health AIDS reagent program. Primary M-tropic isolates (BL-6 and CSF-6) were isolated from the blood and cerebrospinal fluid cells, respectively, of a subject with AIDS. Seven-day-cultured macrophages in 24-well plates (1 ϫ 10 6 cells͞well) were incubated with or without CP-96,345 or its inactive enantiomer, CP-96,344, for 2 h before infection with HIV. The cells were also incubated with SP and͞or anti-SP antibody. In this case, SP was incubated with (1:1,000 dilution in 10% FCS DMEM) or without anti-SP antibody at room temperature for 10 min, and then the mixture was added to the cell cultures for 2 h. When the cells were treated with the combination of CP-96,345 and SP, or CP-96,345, SP and anti-SP antibody, CP-96,345 was incubated with the cell culture for 10 min; SP was then added to the MDM, or CP-96,345, SP, and anti-SP (1:1,000 in 10% FCS DMEM) were incubated for 10 min at room temperature, and the mixture was incubated with the MDM for 2 h before infection with HIV. Untreated MDM served as controls. The cells were treated before, during, and throughout the infection.
HIV infection. After 2 h incubation with or without the reagents described above, the cells were infected with equal amounts of cell-free HIV based on p24 antigen content (20 ng͞10 6 cells) overnight, and then washed to remove unbound virus. Fresh media containing SP and͞or CP-96,345 or anti-SP antibody were added to the MDM as described above. The culture media and the reagents were replaced twice weekly. The culture supernatants were harvested for HIV reverse transcriptase (RT) activity determinations. After HIV infection, the MDM were incubated 8-12 days. At the termination of the experiments, cellular RNA was extracted for assessment of HIV gag gene expression by using RT-PCR or real-time RT-PCR assays.
HIV RT Assay. The HIV RT activity assay was carried out based on the technique of Willey et al. (30) with modification (22) . Syncytia Formation. To study the effect of CP-96,345 on HIVinduced syncytia formation in MDM, 7-day-cultured macrophages were incubated in the presence or absence of CP-96,345 (10 Ϫ7 M) for 2 h and then infected with HIV Bal strain. MDM that was neither incubated with CP-96,345 nor infected with HIV was used as a cell culture control. The morphology of HIVinduced syncytia formation was observed and photographed by a light microscopy (400ϫ) 12 days after HIV infection.
Pseudotype Reporter Virus Entry Assay. Recombinant luciferaseencoding HIV virions pseudotyped with Env from the M-tropic ADA (CCR5-dependent) and amphitropic murine leukemia virus (MLV) (CCR5-independent) were used to study HIV infection of MDM incubated with or without CP-96,345. The Env-deleted luciferase reporter plasmid PNL-Luc-E-Rϩ (kindly provided by N.
Landau, The Salk Institute for Biological Studies, La Jolla, CA) was cotransfected into 293T cells along with plasmids encoding the ADA or MLV Env genes as described (31) . Supernatants were collected 48 h later, assayed for p24 Gag antigen content, and frozen at Ϫ80°C. MDM (2.5 ϫ 10 5 ͞well in 48-well plates) were incubated overnight with or without CP-96,345 and then infected by using 20 ng of p24 Gag antigen equivalent of each pseudotype HIV per well, in the presence of polybrene (7.5 g͞ml). At 72 h postinfection, the cells were lysed in 150 l of 0.5% Triton-X-100 in PBS. Lysate (50 l) was mixed with an equal volume of luciferase substrate (Promega), and luciferase activity was determined in a microtiter plate luminometer (Dynex Technologies, Chantilly, VA). The results were expressed as relative light units in CP-96,345-treated and infected MDM as a percentage of that in untreated and infected MDM.
CAT Activity Assay. U38 cells (2 ϫ 10 6 cells) were incubated with different concentrations of SP and͞or CP-96,345 for 48 h. Untreated U38 cells were used as a background control. Cellular proteins were extracted by using 1ϫ reporter lysis buffer (Promega). The lysates were incubated with a mixture containing 0.15 Ci of 14 C-labeled chloramphenicol (DuPont) and 200 g͞ml n-butyryl CoA (Promega) in a total volume of 125 l at 37°C for 3 h. The acetylated forms of chloramphenicol were extracted with xylene (Aldrich). CAT activity of each sample was quantified by using a liquid-scintillation counter (Packard). The results were expressed as the ratio of CAT activity (cpm) of the SP and͞or CP-96,345-treated U38 to that of the background control. RNA Isolation. Total RNA was isolated from human peripheral blood MDM (10 6 cells) by using Tri-Reagent (Molecular Research Center, Cincinnati) as reported (16) .
Reverse Transcription. Total RNA (1 g) was reverse transcribed by using the reverse transcription system (Promega) with the specific primers (antisense) for HIV gag (5Ј-TGACATGCTGT-CATCATTTCTTC-3Ј) (27) or CCR5 (5Ј-CCTGTGCCTCT-TCTTCTCATTTCG-3Ј) (32) for 1 h at 42°C. RT reactions were terminated by incubating the reaction mixture at 99°C for 5 min and then kept at 4°C. The resulting cDNA was used as a template for PCR amplification or real-time PCR quantification. PCR Analysis. PCR amplification of CCR5 and HIV gag cDNA was performed with one-tenth of the cDNA for 35 cycles (CCR5) (32) or 40 cycles (gag) (27) by using AmpliTaq Gold (PerkinElmer͞Cetus) in a GeneAmp PCR System 2400 (PerkinElmer͞Cetus). ␤-actin was used as a control to monitor the amount and integrity of RNA in each sample (CLONTECH). Real-time PCR was performed with one-tenth of cDNA by using the ABI Prism 7700 sequence detection system (Perkin-Elmer). The reaction mixture contained 0.25 mM dNTPs, AmpliTaq Gold (1.5 units), 5 mM MgCl 2 , 50 pmol of each of the two primers (SK 38, 5Ј-ATA ATCCACCTATCCCAGTAG-GAGAAAT-3Ј; SK39, 5Ј-TTTGGTCCTGTCTTATGTCCA-GAATGC-3Ј), 20 pmol of the molecular beacon probe (SK19, 5Ј-ATCCTGGGGAT TA A ATA A A ATAGTA AGA ATG-TATAGCCCTAC-3Ј) labeled with FAM (a fluorophore) at its 5Ј end and DABCYL (a quencher) at the 3Ј end. The cycle conditions were 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The known amounts of HIV DNA isolated from ACH-2 cells were used as standard controls. All standards and samples were run in duplicates. HIV gag, CCR5, ␤-actin primer pairs, and the probe (SK19) were synthesized by Integrated DNA Technologies (Coralville, IA).
CP-96,345 Treatment and Cytokine Production.
To determine the role of CP-96,345 in the regulation of cytokine secretion, 7-daycultured MDM were incubated with or without CP-96,345 (10 Ϫ9 to 10 Ϫ7 M) and͞or LPS (1 ng͞ml) for 24 h. The culture supernatants were collected to determine TNF-␣ and IL-6 levels by ELISA. The ELISA kits were purchased from Endogen (Cambridge, MA).
Statistical Analysis. The data were analyzed by using the Student's t test for paired samples.
Results
Effect of SP and͞or CP-96,345 on HIV Replication in MDM. SP up-regulated HIV replication in MDM in a concentrationdependent fashion (Fig. 1A) , which is consistent with our previous observation (22) . HIV RT activity was increased by 14% (10 (Fig. 1 A) . We thus determined whether the addition of CP-96,345 to MDM could inhibit HIV Bal strain infection of MDM. As shown in (Fig. 2) . To further examine the inhibition of CP-96,345 on HIV Bal strain at mRNA level, HIV gag gene expression was measured by using RT-PCR. HIV gag mRNA expression was potently inhibited by CP-96,345 treatment in a concentrationdependent fashion (Fig. 3A) . To quantitatively measure mRNA copy numbers for HIV gag gene, we used real-time RT-PCR to quantify the same samples shown in Fig. 3A . Of note and most important to the findings reported here, CP-96,345 significantly suppressed HIV gag gene mRNA expression at all three concentrations tested (Fig. 3B) .
CP-96,345 Inhibited HIV Replication by Antagonism of NK-1R on MDM.
To determine whether inhibition of CP-96,345 on HIV infection of MDM is mediated by specific antagonism of NK-1R, MDM were incubated with CP-96,345 or its inactive enantiomer CP-96,344 for 2 h and then infected with HIV Bal strain. In comparison with the HIV infection control, viral replication was inhibited by CP-96,345 treatment (10 Ϫ7 M), whereas CP-96,344 at the same concentration did not have the effect as determined by HIV RT activity (Fig. 4) , demonstrating that CP-96,345 affected HIV replication through antagonism of NK-1R on MDM. To further test our hypothesis that SP-NK-1R interaction plays a role and is a necessary component in HIV replication in MDM, we incubated MDM with SP in the presence or absence of CP-96,345 or anti-SP antibody, or both for 2 h, and then infected the MDM with HIV Bal strain. As expected, SP alone enhanced HIV replication, whereas CP-96,345, anti-SP antibody, and the combination of both abrogated SP-enhanced HIV replication in MDM as determined by HIV RT activity and HIV gag mRNA levels (Fig. 5) . Furthermore, treatment with CP-96,345 and͞or anti-SP antibody down-regulated HIV replication to a level that was even lower than that of the HIV infection control (Fig. 5) . The combination of anti-SP antibody and CP-96,345 had a synergistic effect on HIV replication in MDM, further demonstrating that both SP and SP receptors are involved in HIV infection of MDM and that interruption of SP autocrine loop resulted in inhibition of HIV replication in these cells (Fig. 5) .
Effect of CP-96,345 on HIV Replication. To determine the effect of CP-96,345 on different HIV tropic strains (R5, X4, and R5X4), MDM were incubated with or without CP-96,345 (10 Ϫ7 M) and then infected with R5 strains (Bal, ADA, CSF-6, and BL-6), R5X4 strain (89.6), or X4 strain (UG024). In contrast to the prototype T cell line-adapted X4 strains, UG024 is capable of by using macrophage CXCR4 for infection (33) , whereas 89.6 uses both macrophage CXCR4 and CCR5 (34) . The replication of all R5 strains studied, including both prototype strains and primary isolates, was inhibited by CP-96,345 treatment, whereas the R5X4 strain (89.6) was inhibited to a lesser extent and the X4 strain (UG024) was not affected (Fig. 6) .
Effect of SP on Activation of HIV LTR-Driven CAT Activity in U38 Cell
Line. To determine whether SP activates HIV LTR promoter, we used U38 cells as a model for the experiments. SP significantly increased HIV LTR-driven CAT activity at the concentrations of 10 vates HIV LTR through the interaction with NK-1R on the cell membrane (Fig. 7) .
Effect of CP-96,345 on Macrophage Receptor Expression. Because the replication of the HIV R5 strains but not the X4 strain was inhibited by CP-96,345, we hypothesized that the SP-NK-1R interaction participated in the regulation of HIV coreceptor CCR5 expression. To examine the effect of CP-96,345 on HIV receptor expression, MDM were incubated overnight with or without CP-96,345 or CP-96,344. Among the CD4, CCR5, CXCR4, and CD14 receptors, only CCR5 expression was downregulated by CP-96,345, whereas CP-96,344 did not affect CCR5 receptor expression (Fig. 8) . CCR5 mRNA was also downregulated in MDM by CP-96,345 (10 (Fig. 9) .
Effect of CP-96,345 on HIV Pseudotype Infection of MDM.
To examine the functional relevance of CP-96,345-mediated CCR5 downregulation to HIV infection of MDM, the cells incubated with or without CP-96,345 were infected with luciferase-encoding HIV virions pseudotyped with either ADA Env (CCR5-dependent) or MLV Env (CCR5-independent). We observed that CP-96,345 inhibited M-tropic ADA infection of MDM as demonstrated by luciferase activity (Fig. 10) . However, CP-96,345 failed to block MLV Env-pseudotyped HIV infection of MDM, indicating that the major effect of CP-96,345 inhibition is regulated by Envdetermined early events in HIV entry into MDM.
Effect of CP-96,345 on TNF-␣ Synthesis in MDM.
To determine whether SP participates in TNF-␣ synthesis in an autocrine fashion, the effect of CP-96,345 on LPS-stimulated TNF-␣ production in MDM was determined by ELISA. CP-96,345 attenuated LPS-stimulated TNF-␣ production in MDM in a concentration-dependent manner, whereas IL-6 production was not affected (Fig. 11) , indicating that the SP is involved in the regulation of TNF-␣ synthesis and secretion in an autocrine fashion.
Discussion
In this communication, we have demonstrated that the SP antagonist, CP-96,345, potently inhibited HIV (R5 strains) replication in human peripheral blood MDM. Because SP is involved in the modulation of HIV infection of MDM (Fig. 1 A) (22) and there is an autocrine regulation of SP (8-10) (Fig. 11) , the observed inhibition is the consequence of the interruption of SP autocrine loop through antagonism of SP-NK-1R interaction on the cell membrane. The following data strongly support this hypothesis: (i) both CP-96,345 and anti-SP antibody inhibited SP-enhanced HIV Bal strain replication in MDM (Figs. 1B, 3 , and 5); (ii) CP-96,345 inhibited HIV R5 strain replication in MDM, whereas its inactive enantiomer, CP-96,344, was ineffective (Fig. 4) ; and (iii) the HIV R5 (CCR5-dependent) strain replication was inhibited, whereas the R5X4 dual tropic strain (89.6) and the X4 (UGO24) strain were partially inhibited or not affected, respectively (Fig. 6) .
Furthermore, we observed that CP-96,345 down-regulated CCR5 expression in MDM, whereas CP-96,344, the inactive enantiomer of CP-96,345, was ineffective (Figs. 8 and 9 ). Downregulation of CCR5 is functionally relevant to the decreased susceptibility to HIV infection by MDM (Fig. 10 ). This obser- Fig. 9 . Effect of CP-96,345 on CCR5 mRNA expression in MDM. Ϫ, PCR negative control, which represents lack of PCR products when RT was omitted from the RT reaction by using RNA extracted from untreated MDM. MDM only, untreated MDM was used as a control. MDM were incubated with CP-96,345 (10 Ϫ8 to 10 Ϫ6 M) as indicated for 3 h, and CCR5 mRNA was then amplified by using RT-PCR. M, 100-bp DNA ladder coelectrophoresed as markers. ␤-actin was used to monitor the amount and integrity of RNA in each sample. vation is further supported by the findings that CP-96,345 inhibited the replication of HIV R5 strains (Bal, ADA, CSF-6, and BL-6) but not the X4 strain (UGO24) (Fig. 6 ) and that only ADA Env-pseudotyped HIV infection was inhibited (Fig. 10) . These data strongly indicate that SP autocrine loop is involved in the regulation of CCR5 expression in MDM and that downregulation of CCR5 expression on MDM by CP-96,345 is caused by an interruption of this autocrine loop in these cells. The precise mechanism(s) whereby SP-NK-1R interaction regulates CCR5 expression requires further investigation. SP activates NF-B (1, 2, 35 ), which is a potent activator of the CCR5 promoter (36) and participates in the regulation of TNF-␣ expression and secretion in vitro and in vivo (9, (37) (38) (39) (40) . Pretreatment of mice with an SP antagonist down-regulated LPSstimulated TNF-␣ transcription and secretion in vivo (39) . Furthermore, our studies demonstrated that CP-96,345 attenuated LPS-stimulated TNF-␣ secretion in human MDM (Fig. 11) . Recent studies have demonstrated that TNF-␣ up-regulates CCR5 expression in macrophages (41) and peripheral blood mononuclear cells (42) and altered HIV expression in monocytes in vitro (6, 7) . Thus, CP-96,345-mediated TNF-␣ regulation may be partially responsible for the down-regulation of CCR5 expression in MDM. Further investigation is needed to determine the mechanism(s) whereby CP-96,345-NK-1R interaction regulates CCR5 expression in relation to HIV infection of human MDM.
Although the precise mechanism(s) by which CP-96,345 inhibits HIV R5 strain replication could not be ascertained from the present study, our data strongly support two coexisting potential mechanisms. One possibility is that CP-96,345 interrupts the SP autocrine loop, which may play a role in maintaining high-level CCR5 expression, permitting HIV R5 strain infection at the virus entry level. A second possibility is that CP-96,345 inhibits SPstimulated HIV replication at the transcriptional level because the addition of SP to MDM cultures did not affect CCR5 expression (data not shown) but did enhance HIV replication (Figs. 1 A and 5) and HIV LTR-driven CAT gene expression. This effect of SP was abrogated by preincubated MDM with CP-96,345 (Fig. 7) . Moreover, we observed that CP-96,345 did not suppress HIV LTRdriven CAT activity below the control level (Fig. 7) as observed in Fig. 5 for HIV RT activity and gag mRNA copy numbers. This finding provides additional evidence that supports our hypothesis that the mechanism by which CP-96,345 inhibits HIV infection of MDM was mainly because of its suppressive effect on CCR5 expression. In addition, the neutralization of SP by anti-SP antibody resulted in down-regulation of HIV replication in MDM, and the combination of anti-SP antibody and CP-96,345 had a synergistic effect on HIV replication in MDM (Fig. 5) . These findings indicate that both SP and its receptor (NK-1R) are indeed involved in HIV infection of MDM. Although the specific factors involved in SP-stimulated HIV replication in these immune cells are not yet known, our findings provide further evidence that there is an important link between neuropeptide SP and HIV infection of human immune cells.
Taken together, these in vitro effects of the SP antagonist CP-96,345, including attenuation of TNF-␣ production in MDM, down-regulation of CCR5 receptor expression on MDM, and inhibition of HIV R5 strain replication in MDM, may offer approaches to the design of new anti-HIV therapeutics. Studies of the mechanism(s) of SP action in the regulation of immune responses in HIV infection of MDM and the direct and͞or indirect effect of SP-NK-1R interaction on HIV infection of and replication in human MDM and other immune cells will be beneficial.
